MyLungCancerTeam

Sotorasib, also known by its brand name Lumakras, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. Here are some key points:

- Show Full Answer

Sotorasib, also known by its brand name Lumakras, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. Here are some key points:

- Mechanism: Lumakras targets the KRAS G12C protein, a common mutation in certain cancers, disrupting cancer cell growth and survival.
- Administration: Taken orally once daily, with or without food.
- Side Effects: Common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity (liver damage), and cough. Serious side effects may include interstitial lung disease or pneumonitis.
- Monitoring: Regular liver function tests are recommended to monitor for hepatotoxicity.

For more detailed information, you can visit the Lumakras page on MyLungCancerTeam.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Lumakras (Sotorasib) for Lung Cancer | MyLungCancerTeam

Lorbrena (Lorlatinib) for Lung Cancer | MyLungCancerTeam